SLP Simulations Plus, Inc.: Koefisien utang jangka dawa marang modal

Logo korporat perusahaan Simulations Plus, Inc. (SLP)

This chart of Simulations Plus, Inc. (SLP) price action reflects the dynamics of a company whose authority in developing pharmaceutical software is validated by the trust of leading global behemoths. The current indicator stands at 0.00. The business faces barriers of national protectionism and data storage requirements, which are hindering expansion. Meanwhile, the firm is recruiting AI experts, leveraging a unique staff of programmers within a narrow niche.

Simulations Plus, Inc. (SLP): Utang jangka dawa marang modal saka 04.07.2022 nganti 18.10.2026
Produk merek Simulations Plus

To minimize fundamental risks, investors should select assets with a low long-term debt-to-equity ratio, which determines the degree of financial autonomy and resilience to default. This long-term debt coverage ratio confirms the ability of Simulations Plus, Inc. (SLP) to finance high-tech ESG software for computer-aided drug modeling without excessive credit leverage, reflecting the real value of the business.

Perusahaan pesaing

Rasio silihan jangka dawa marang modal Veeva Systems (VEEV)|Doximity Corp (DOCS) - Rasio utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal HQY (HealthEquity Building)|Waystar Holding Corp. - Utang jangka dawa marang ekuitas|Rasio utang jangka dawa marang ekuitas corvel.com CRVL|PRVA (Privia Health) - Utang jangka dawa marang modal|HURN - Kewajiban jangka dawa marang modal|Utang jangka dawa marang modal Certara Corp|OMCL (Omnicell Health) - Rasio utang jangka dawa marang modal|GDRX: Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka dawa marang modal schrodinger.com|PHR (Phreesia) - Utang jangka dawa marang modal|Rasio tanggungan utang jangka dawa marang modal OMDA (Omada Health, Inc.)|Evolent - Utang jangka dawa marang ekuitas|HSTM - Rasio utang jangka dawa marang ekuitas|Definitive Healthcare - Rasio utang jangka dawa marang ekuitas|CCSI: Utang jangka dawa marang modal|agilon health (AGL) - Utang jangka dawa marang ekuitas|Absci Corp (ABSI) - Utang jangka dawa marang ekuitas|SY (SoYoung) - Utang jangka dawa marang modal|Utang jangka dawa marang modal nrchealth.com (NRC)|Rasio utang jangka dawa marang ekuitas Spok Holdings, Inc.|Rasio silihan jangka dawa marang modal optimizerx.com (OPRX)|Utang jangka dawa marang modal TBRG|Sophia Genetics - Rasio tanggungan utang jangka dawa marang modal|HCAT (Health Catalyst, Inc) - Utang jangka dawa marang ekuitas|CCLD: Kewajiban jangka dawa marang modal|Utang jangka dawa marang ekuitas Research Solutions|DLHC (DLH Holdings) - Rasio utang jangka dawa marang modal|ONMD: Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka dawa marang modal Scienture Holdings (SCNX)|Healthcare Triangle Corp (HCTI) - Rasio utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal ISPC (ispecimen.com)|Bullfrog AI (BFRG) - Utang jangka dawa marang ekuitas|scworx.com - Kewajiban jangka dawa marang ekuitas|MSPR - Utang jangka dawa marang ekuitas|iCoreConnect Inc. (ICCT) - Utang jangka dawa marang ekuitas|MEDS: Rasio utang jangka dawa marang ekuitas|ORGS (Orgenesis Corporation) - Utang jangka dawa marang modal|RCM: Utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka dawa marang modal sharecare.com (SHCR)|Streamline Health (STRM) - Rasio utang jangka dawa marang ekuitas|Koefisien utang jangka dawa marang modal Syra Health Corp (SYRA)|Utang jangka dawa marang modal AMEH|Model N Corporation - Rasio tanggungan utang jangka dawa marang modal|NextGen Healthcare (NXGN) - Utang jangka dawa marang ekuitas